These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 26536316)

  • 21. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration.
    Sabin CA; Reiss P; Ryom L; Phillips AN; Weber R; Law M; Fontas E; Mocroft A; de Wit S; Smith C; Dabis F; d'Arminio Monforte A; El-Sadr W; Lundgren JD;
    BMC Med; 2016 Mar; 14():61. PubMed ID: 27036962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term safety and tolerability of the lamivudine/abacavir combination as components of highly active antiretroviral therapy.
    Castillo SA; Hernandez JE; Brothers CH
    Drug Saf; 2006; 29(9):811-26. PubMed ID: 16944966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renal toxicity of long-term therapy with tenofovir in HIV-infected patients.
    Monteagudo-Chu MO; Chang MH; Fung HB; Bräu N
    J Pharm Pract; 2012 Oct; 25(5):552-9. PubMed ID: 22551561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic kidney disease and HIV in the era of antiretroviral treatment: findings from a 10-year cohort study in a west African setting.
    Kaboré NF; Poda A; Zoungrana J; Da O; Ciaffi L; Semdé A; Yaméogo I; Sawadogo AB; Delaporte E; Meda N; Limou S; Cournil A
    BMC Nephrol; 2019 May; 20(1):155. PubMed ID: 31064340
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of abacavir on acute changes in biomarkers associated with cardiovascular dysfunction.
    Patel P; Bush T; Overton T; Baker J; Hammer J; Kojic E; Conley L; Henry K; Brooks JT;
    Antivir Ther; 2012; 17(4):755-61. PubMed ID: 22301072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.
    Carr A; Workman C; Smith DE; Hoy J; Hudson J; Doong N; Martin A; Amin J; Freund J; Law M; Cooper DA;
    JAMA; 2002 Jul; 288(2):207-15. PubMed ID: 12095385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic events in HIV-infected patients using abacavir are associated with erythrocyte inosine triphosphatase activity.
    Peltenburg NC; Bierau J; Schippers JA; Lowe SH; Paulussen ADC; van den Bosch BJC; Leers MPG; Andrinopoulou ER; Bakker JA; Verbon A
    J Antimicrob Chemother; 2019 Jan; 74(1):157-164. PubMed ID: 30304447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.
    Martínez E; Arranz JA; Podzamczer D; Loncá M; Sanz J; Barragán P; Ribera E; Knobel H; Roca V; Gutiérrez F; Blanco JL; Mallolas J; Llibre JM; Clotet B; Dalmau D; Segura F; Arribas JR; Cosín J; Barrufet P; Casas E; Ferrer E; Curran A; González A; Pich J; Cruceta A; Arnaiz JA; Miró JM; Gatell JM;
    J Acquir Immune Defic Syndr; 2009 Jul; 51(3):290-7. PubMed ID: 19398921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.
    Martínez E; Larrousse M; Podzamczer D; Pérez I; Gutiérrez F; Loncá M; Barragán P; Deulofeu R; Casamitjana R; Mallolas J; Pich J; Gatell JM;
    AIDS; 2010 Jan; 24(3):F1-9. PubMed ID: 20009917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HLA- B*5701 Allele in HIV-infected Indian Children and its Association with Abacavir Hypersensitivity.
    Manglani MV; Gabhale YR; Lala MM; Sekhar R; More D
    Indian Pediatr; 2018 Feb; 55(2):140-141. PubMed ID: 29242412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects.
    Brothers CH; Hernandez JE; Cutrell AG; Curtis L; Ait-Khaled M; Bowlin SJ; Hughes SH; Yeo JM; Lapierre DH
    J Acquir Immune Defic Syndr; 2009 May; 51(1):20-8. PubMed ID: 19282778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse events associated with abacavir use in HIV-infected children and adolescents: a systematic review and meta-analysis.
    Jesson J; Dahourou DL; Renaud F; Penazzato M; Leroy V
    Lancet HIV; 2016 Feb; 3(2):e64-75. PubMed ID: 26847228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
    Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
    AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Abacavir and CVD--again.
    Sax PE
    J Watch AIDS Clin Care; 2009 Oct; 21(10):81. PubMed ID: 20458812
    [No Abstract]   [Full Text] [Related]  

  • 36. Incidence of abacavir hypersensitivity reactions in euroSIDA.
    Bannister WP; Friis-Møller N; Mocroft A; Viard JP; van Lunzen J; Kirk O; Gargalianos P; Bánhegyi D; Chiesi A; Lundgren JD;
    Antivir Ther; 2008; 13(5):687-96. PubMed ID: 18771052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abacavir and cardiovascular disease: A critical look at the data.
    Llibre JM; Hill A
    Antiviral Res; 2016 Aug; 132():116-21. PubMed ID: 27260856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.
    Saumoy M; Ordoñez-Llanos J; Martínez E; Barragán P; Ribera E; Bonet R; Knobel H; Negredo E; Loncá M; Curran A; Gatell JM; Podzamczer D;
    Antivir Ther; 2011; 16(4):459-68. PubMed ID: 21685533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team.
    Saag MS; Sonnerborg A; Torres RA; Lancaster D; Gazzard BG; Schooley RT; Romero C; Kelleher D; Spreen W; LaFon S
    AIDS; 1998 Nov; 12(16):F203-9. PubMed ID: 9833848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study.
    De Luca A; de Gaetano Donati K; Cozzi-Lepri A; Colafigli M; De Curtis A; Capobianchi MR; Antinori A; Giacometti A; Magnani G; Vullo V; Cauda R; Iacoviello L; d'Arminio Monforte A;
    J Acquir Immune Defic Syndr; 2012 Jul; 60(3):e98-101. PubMed ID: 22728753
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.